

REMARKS

Following entry of this amendment, the entry of which is respectfully requested, claims 1, 5-7, 11, 29, and 35-40 will be pending in this application. Claims 2, 3, 25-28, and 30-34 are canceled herein without prejudice or disclaimer, and claims 1 and 29 are currently amended. Support for the amendments can be found throughout the specification and claims as originally filed, e.g., at paragraphs [0010] and [0034]. No new matter has been added.

Claims 1-3, 5-7, 11, 25-28, 30-34, and 40 were rejected as allegedly not enabled for the full scope of the claims. Applicants disagree with the rejection for at least the reasons of record. Solely to advance prosecution, applicants have amended claim 1 to recite that the at least one vaccination of DC comprises autologous DC that present autologous glioma antigens. Applicants submit that this obviates the rejection, and request reconsideration and withdrawal thereof.

Applicants submit that the pending claims are allowable and request early and favorable action thereon. Applicants do not concede any positions of the Office that are not expressed above, nor do applicants concede that there are not other good reasons for patentability of the presented claims or other claims.

If it would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at 617-521-7020.

Please apply any required charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 22862-0004US1.

Respectfully submitted,

Date: December 17, 2010

/RSMcQuade/  
Ryan S. McQuade, Ph.D.  
Reg. No. 61,358

Customer Number 26161  
Fish & Richardson P.C.  
Telephone: (617) 542-5070  
Facsimile: (877) 769-7945